Moleculin Biotech, Inc. announced updates to its active site status and recruitment for the Phase 3 'MIRACLE' trial.
The company is on track to recruit 45 patients in Q4 for initial data unblinding.
Expansion plans include adding 8 new active sites by the end of September and recruiting a total of 20 subjects by the same time.
Global Expansion
Recruitment expanded to countries like Spain, Poland, Italy, and the US.
Site Expansion
Adding 8 new active sites, aiming for 20 total sites recruiting.
Recruitment Goals
Targeting to treat, enroll, or screen 20 subjects by the end of September.
Data Insights
Setting solid groundwork to recruit the 45th subject in Q4 for preliminary data assessment.
- The company's focus on global expansion showcases dedication to advancing the 'MIRACLE' trial.
- Recruitment progress indicates operational efficiency and investor confidence in the trial's success.
Moleculin Biotech's accelerated recruitment efforts and expansion plans reflect promising progress in the 'MIRACLE' trial. Investors can anticipate significant milestones in the coming months.